Jan Vagedes

Dr. Jan Vagedes

Department of Neonatology, University Hopital, University Tübingen
+1
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2020 in Applied Psychophysiology and Biofeedback
Verified
Journal Article
Open access
PDF file
ABAmelie Edith Brinkmann
Amelie Edith Brinkmann
SPSophia Antonia Press
Sophia Antonia Press
EHEduard Helmert
Eduard Helmert
MHMartin Hautzinger
Martin Hautzinger
IKInna Khazan
Inna Khazan
JVJan Vagedes
Jan Vagedes
Psychophysiological disorders due to work-related stress continue to be highly costly for health systems and approaches for cost-effective and easily accessible interventions are much needed. Both heart rate variability-biofeedback (HRV-Bfb) and mindfulness-based interventions (MBI) have been empirically shown to reduce stress. This study compares these two interventions in the work context to a wait-list-control-group (WLC). In this three-armed randomized controlled trial (RCT), 69 healthy adults employed in the same organization were randomized to participate in HRV-Bfb, MBI or the WLC. Participants were assessed for psychophysiological parameters of stress (stress perception, coping, HRV parameters and cortisol) and stress related symptoms (depressive symptoms, psychological wellbeing, mindfulness and self-compassion). Participants trained using either HRV-Bfb or MBI for 6 weeks on a daily basis. Outcomes were assessed at baseline, after the intervention and at follow-up 12 weeks later. Results did not show any statistically significant differences between HRV-Bfb and MBI groups, and neither of the intervention groups (IGs) differed from the WLC. Findings suggest an overall reduction in stress for all groups, including the WLC, with mostly small to medium effect sizes. However, it is important to note that participants with higher baseline stress levels might benefit more from mindfulness and biofeedback-based stress reduction interventions. The results have to be interpreted with caution due to the relatively small sample size. MBI might have a slightly stronger effect on stress reduction in comparison to HRV-Bfb, as suggested by the effect sizes. This study highlights issues and challenges of the implementation of such interventions in corporate health management.

1 December 2018 in Complementary Therapies in Medicine
Verified
Journal Article
Closed access
ARA. Ranger
A. Ranger
EHE. Helmert
E. Helmert
TBT.S. Bott
T.S. Bott
TOT. Ostermann
T. Ostermann
HAH. Als
H. Als
JVJan Vagedes
Jan Vagedes

18 June 2016 in Molecules
Verified
Journal Article
Open access
PDF file
JHJulia Hoffmann
Julia Hoffmann
FCFederica Casetti
Federica Casetti
UBUte Bullerkotte
Ute Bullerkotte
BHBirgit Haarhaus
Birgit Haarhaus
JVJan Vagedes
Jan Vagedes
UWUte Wölfle
Ute Wölfle
Potentilla erecta (PE) is a small herbaceous plant with four yellow petals belonging to the Rosaceae family. The rhizome of PE has traditionally been used as an antidiarrheal, hemostatic and antihemorrhoidal remedy. PE contains up to 20% tannins and 5% ellagitannins, mainly agrimoniin. Agrimoniin is a hydrolyzable tannin that is a potent radical scavenger. In this study we tested the anti-inflammatory effect of four PE fractions with increasing amounts of agrimoniin obtained by Sephadex column separation. First, we analyzed in HaCaT keratinocytes the expression of cyclooxygenase-2 (COX-2) induced by ultraviolet-B (UVB) irradiation. As COX-2 catalyzes the metabolism of arachidonic acid to prostanoids such as PGE2, we also measured the PGE2 concentration in cell culture supernatants. PE inhibited UVB-induced COX-2 expression in HaCaT cells and dose-dependently reduced PGE2. The PE fraction with the highest agrimoniin amount (PE4) was the most effective in this experiment, whereas fraction PE1 containing mainly sugars had no effect. PE4 also dose dependently inhibited the phosphorylation of the epidermal growth factor receptor (EGFR) which plays a crucial role in UVB-mediated COX-2 upregulation. A placebo-controlled UV-erythema study with increasing concentrations of PE4 demonstrated a dose dependent inhibition of UVB-induced inflammation in vivo. Similarly, PE4 significantly reduced UVB-induced PGE2 production in suction blister fluid in vivo. In summary, PE fractions with a high agrimoniin content display anti-inflammatory effects in vitro and in vivo in models of UVB-induced inflammation.

1 February 2019 in Complementary Therapies in Medicine
Verified
Journal Article
Closed access
JVJan Vagedes
Jan Vagedes
AFAurelia Fazeli
Aurelia Fazeli
ABAnna Boening
Anna Boening
EHEduard Helmert
Eduard Helmert
BBBettina Berger
Bettina Berger
David MartinDavid Martin
David Martin

1 October 2018 in Complementary Therapies in Medicine
Verified
Journal Article
Closed access
SBSarah Bieligmeyer
Sarah Bieligmeyer
EHE. Helmert
E. Helmert
MHMartin Hautzinger
Martin Hautzinger
JVJan Vagedes
Jan Vagedes

1 January 2021 in Complementary Therapies in Medicine
Verified
Journal Article
Open access
JVJan Vagedes
Jan Vagedes
EHEduard Helmert
Eduard Helmert
SKSilja Kuderer
Silja Kuderer
KVKatrin Vagedes
Katrin Vagedes
JWJohannes Wildhaber
Johannes Wildhaber
FAFrank Andrasik
Frank Andrasik
Evidence supports the Buteyko breathing technique (BBT) as reducing medication and improving control and quality of life in adults with asthma, but having minimal impact on spirometry. For children with asthma, evidence addressing the utility of BBT is sparse. We evaluated the effectiveness of BBT in managing various aspects of asthma in children. Thirty-two children with partly controlled asthma (age 6-15 years, 66% male) were randomized to either Treatment as Usual (TAU) or TAU combined with Buteyko training (Buteyko group, BG). Children in the BG received an intensive five-day training followed by three months of home practice. Primary outcome was bronchodilator reduction. Secondary outcomes were changes in physiological parameters FEV1_AR (at rest), FEV1_ER (after ergometry), FEV1_BR (after bronchospasmolysis), corticosteroid use, FeNO, SpO2, breath-hold test and questionnaire data [Asthma Control Questionnaire and Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ)]. All measures were collected at Baseline and a three-month follow-up. For the primary outcome, no significant between-group difference was found. Regarding the secondary outcomes, children receiving treatment augmented with BBT revealed significantly greater improvement at the follow-up than those receiving TAU for FEV1_AR (p = .04, d=-0.50), FEV1_ER (p = .02, d=-0.52), and the emotional function subscale of the PACQLQ (p < .01, d = 1.03). No between-group differences were found for the remaining secondary measures of outcome. Our preliminary findings suggest that the addition of BBT to treatment as usual for children with asthma enhances outcomes with respect to spirometry and parental emotional function but does not lead to reductions in medication, at least over the short term.